GET DAILY SIGNALSWhy Is OneMedNet Corporation (ONMD) Stock Up +5.06% Today?
Key Takeaways
- ONMD shares climbed roughly +5.06% to about $5.40, up from the prior session's close of $5.14.
- The primary catalyst was a company release disclosing approximately $18.76 million in year-to-date contracted bookings and a "OneMedNet by the Numbers" growth recap.
- The move extends momentum from Friday, when preliminary third-quarter revenue and fourth-quarter outlook lifted the stock more than 20%.
- Broader context centers on accelerating demand for AI-ready, regulatory-grade Real-World Data (RWD) in life sciences and healthcare.
- Traders are watching whether contracted bookings convert into recognized revenue and the upcoming quarterly earnings report.
- Explore detailed Price Targets, Earnings, and Forecast pages for deeper analysis of ONMD.
- For AI-driven trading ideas across thousands of tickers, explore Trending AI Robots.
Opening Summary
OneMedNet Corporation (ONMD) is a healthcare data and technology company that curates regulatory-grade, AI-ready Real-World Data through its iRWD platform, pairing de-identified medical imaging with comprehensive clinical records for life sciences firms, medical device makers, and AI developers. In Monday's session, shares advanced about +5.06% to roughly $5.40, up from the previous close of $5.14. The move followed a company announcement detailing strong year-to-date contracted bookings, reinforcing a commercial narrative that first gained traction late last week.
Bookings Announcement Fuels the Move
The day's advance was driven primarily by OneMedNet's disclosure that contracted bookings reached approximately $18.76 million year-to-date as of November 6, 2026. The company framed the figure as nearly 14 times full-year 2025 bookings, with roughly half of 2026 contracts coming from new customers. Investors reacted favorably to the scale of the jump, viewing it as validation of the company's strategy of partnering with established industry players across pharma and foundational AI to shorten contracting cycles and expand its data footprint.
The release also highlighted that the iRWD network now spans more than 2,300 healthcare sites, encompassing over 90 million patient journeys and 270 million studies. The breadth of that network is central to the company's pitch: customers increasingly need high-quality, compliant, multimodal data for drug development, regulatory submissions, and AI model training.
Follow-Through From Preliminary Results
Monday's climb also carried over from Friday's sharp rally, when OneMedNet issued preliminary revenue for the third quarter of 2026 along with fourth-quarter guidance. That catalyst set a bullish tone that appears to have persisted into the new week, with the bookings recap extending and reinforcing the same commercial momentum story. The consecutive announcements have effectively compressed what might otherwise have been multiple sessions of news-driven trading into a sustained upward swing.
Market Context and Trading Activity
The move sits within a broader theme of investor enthusiasm for healthcare technology and AI data infrastructure, where companies positioned at the intersection of clinical data and artificial intelligence have attracted renewed attention. As a micro-cap name in the Health Information Services space, ONMD tends to trade with amplified volatility, and news-driven percentage swings of this magnitude are not unusual for the stock.
Volume on the prior session was elevated relative to the stock's typical activity, consistent with the surge in attention following the company's disclosures. The stock is also rebounding within a wide 52-week range, leaving ample room for sharp moves as traders react to fundamental updates rather than established technical levels.
What Comes Next for ONMD
Looking ahead, the central question for investors is conversion: how quickly the roughly $18.76 million in contracted bookings translates into recognized revenue. As of September 30, 2026, only about $1.388 million of that amount had been converted to revenue, underscoring the gap between contracted demand and near-term financial results that traders will scrutinize.
The upcoming quarterly earnings report will be a key checkpoint for management's outlook on subscription growth and recurring revenue. Sector developments in AI-driven drug discovery and foundational model training also remain relevant, given the company's dependence on customers in those fields. Risks include execution on converting trials to subscriptions, reliance on a concentrated set of large channel partners, and the broader volatility typical of early-stage, low-float healthcare names.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving traders a range of automated approaches to explore. Visit Trending AI Robots to see which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ONMD in -5.38% downward trend, falling for three consecutive days on October 30, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ONMD declined for three days, in 218 of 241 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
ONMD broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ONMD entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ONMD's RSI Indicator exited the oversold zone, 18 of 19 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 35 of 57 cases where ONMD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 61%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on ONMD as a result. In 41 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 51%.
The Moving Average Convergence Divergence (MACD) for ONMD just turned positive on October 21, 2026. Looking at past instances where ONMD's MACD turned positive, the stock continued to rise in 30 of 57 cases over the following month. The odds of a continued upward trend are 53%.
ONMD moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +43.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where ONMD advanced for three days, in 113 of 149 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. ONMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ONMD's P/B Ratio (-86.621) is very low in comparison to the industry average of (4.477). P/E Ratio (-3.024) is within average values for comparable stocks, (13.414). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. ONMD's P/S Ratio (23.529) is slightly higher than the industry average of (6.065).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement